$237 Million is the total value of Affinity Asset Advisors, LLC's 54 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LLY | New | LILLY ELI & COcall | $9,727,000 | – | 30,000 | +100.0% | 4.10% | – |
| ESTA | New | ESTABLISHMENT LABS HLDGS INCput | $8,157,000 | – | 150,000 | +100.0% | 3.44% | – |
| KRTX | New | KARUNA THERAPEUTICS INCput | $5,693,000 | – | 45,000 | +100.0% | 2.40% | – |
| NVAX | New | NOVAVAX INCput | $4,629,000 | – | 90,000 | +100.0% | 1.95% | – |
| NVAX | New | NOVAVAX INCcall | $4,372,000 | – | 85,000 | +100.0% | 1.84% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEWcall | $3,909,000 | – | 145,000 | +100.0% | 1.65% | – |
| LEGN | New | LEGEND BIOTECH CORPcall | $2,750,000 | – | 50,000 | +100.0% | 1.16% | – |
| MRNA | New | MODERNA INCcall | $2,143,000 | – | 15,000 | +100.0% | 0.90% | – |
| FATE | New | FATE THERAPEUTICS INCcall | $1,673,000 | – | 67,500 | +100.0% | 0.70% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INCcall | $1,656,000 | – | 150,000 | +100.0% | 0.70% | – |
| New | ARCELLX INC | $1,356,000 | – | 75,000 | +100.0% | 0.57% | – | |
| COGT | New | COGENT BIOSCIENCES INC | $1,128,000 | – | 125,000 | +100.0% | 0.48% | – |
| TERN | New | TERNS PHARMACEUTICALS INC | $995,000 | – | 401,268 | +100.0% | 0.42% | – |
| SBTX | New | SILVERBACK THERAPEUTICS INC | $721,000 | – | 170,000 | +100.0% | 0.30% | – |
| CYTK | New | CYTOKINETICS INC | $589,000 | – | 15,000 | +100.0% | 0.25% | – |
| ENOB | New | ENOCHIAN BIOSCIENCES INCput | $386,000 | – | 200,000 | +100.0% | 0.16% | – |
| PNT | New | POINT BIOPHARMA GLOBAL INC | $174,000 | – | 25,578 | +100.0% | 0.07% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MORPHIC HOLDING INC | 12 | Q3 2023 | 6.9% |
| KURA ONCOLOGY INC | 12 | Q3 2023 | 7.2% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 1.9% |
| IMMATICS N.V | 12 | Q3 2023 | 0.4% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.4% |
| ESTABLISHMENT LABS HLDGS INC | 11 | Q3 2023 | 8.3% |
| VINCERX PHARMA INC | 11 | Q2 2023 | 4.5% |
| ASCENDIS PHARMA A/S | 11 | Q3 2023 | 4.9% |
| CYTOKINETICS INC | 11 | Q3 2023 | 2.6% |
| INARI MED INC | 10 | Q1 2023 | 6.4% |
View Affinity Asset Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 03, 2023 | 7,477,000 | 9.2% |
View Affinity Asset Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-07 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-21 |
| 13F-HR | 2023-08-14 |
| SC 13G | 2023-07-03 |
| 13F-HR | 2023-05-15 |
View Affinity Asset Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.